Aclaris Therapeutics, INC Schedule 13G passive stakes

RA Capital Management, along with affiliated entities and individuals, has reported a beneficial ownership of 9.1% of Aclaris Therapeutics' common stock as of June 30, 2026.

Vivo Opportunity Fund Holdings and related entities report a combined beneficial ownership of approximately 4.8% in Aclaris Therapeutics, Inc.

BML Investment Partners, L.P. has filed a Schedule 13G reporting a 9.9% beneficial ownership stake in Aclaris Therapeutics, Inc.

RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. have filed a joint Schedule 13G, indicating beneficial ownership of 6.3% of Aclaris Therapeutics, Inc. common stock.

The Vanguard Group has reported a 0% beneficial ownership in Aclaris Therapeutics Inc. following an internal realignment.

Deep Track Capital and its affiliates have reported a 7.0% beneficial ownership stake in Aclaris Therapeutics, Inc., totaling 9,345,000 shares.

BML Investment Partners, L.P. has disclosed a significant 11.9% beneficial ownership stake in Aclaris Therapeutics, Inc. common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.2% beneficial ownership stake in Aclaris Therapeutics, Inc. as of December 31, 2025.

Biosion, Inc.'s wholly-owned subsidiary, Bonita Biotech (HK) Limited, has acquired a 9.4% beneficial ownership stake in Aclaris Therapeutics, Inc. through a warrant exercise.

Adage Capital Management and its principals have reported reducing their beneficial ownership in Aclaris Therapeutics, Inc. to 4.87%.

The Vanguard Group has reported a significant beneficial ownership stake of 6.15% in Aclaris Therapeutics Inc., primarily for investment purposes.

Millennium Management LLC and affiliated entities have reported a 3.5% passive beneficial ownership stake in Aclaris Therapeutics, Inc. common stock.

BlackRock, Inc. has reported a 5.1% beneficial ownership stake in Aclaris Therapeutics, Inc., holding 5,471,711 shares of common stock as of June 30, 2025.

Rock Springs Capital Management LP and its affiliated entities have filed an amendment to their Schedule 13G, reporting a 4.7% beneficial ownership stake in Aclaris Therapeutics, Inc.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has reported a beneficial ownership of 7.6% in Aclaris Therapeutics, Inc. common stock.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly reported a beneficial ownership of 5.1% in Aclaris Therapeutics, Inc. common stock.

The Vanguard Group has filed an amended Schedule 13G, reporting a 4.60% passive ownership stake in Aclaris Therapeutics Inc. as of March 31, 2025.

BML Investment Partners, L.P. has reported a 13.3% beneficial ownership stake in Aclaris Therapeutics, Inc., holding 14.25 million shares as of December 31, 2024.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has disclosed a 9.00% passive beneficial ownership stake in Aclaris Therapeutics, Inc., totaling 9,627,304 shares of common stock.